Briefing

The BPC unites numerous companies throughout the medical cannabis supply chain. How do you develop common positions?  

The Federal Association of Pharmaceutical Cannabinoid Companies represents companies involved in the cultivation, processing, distribution, and research of cannabis. Naturally, different interests converge in this process. While there is much overlap, it is the association’s task to professionally moderate the dialogue between members and maintain the focus on our common goal: ensuring the quality supply of medicinal cannabis in Germany. Transparency, commitment, and a shared vision are the keys to developing strong, professional, and politically viable positions together. 

How can you legitimately represent interests in such a sensitive area as cannabis or medical cannabis? 

At our association, we represent interests in the field of medical cannabis by communicating responsibly, objectively, and in a solution-oriented manner. As an association, we navigate the tension between health policy, social debate, and economic development. Our central task is to distinguish the medical benefits of cannabis from its recreational use and highlight where legal hurdles are hindering an adequate supply. We engage in dialogue with political decision-makers, experts, and authorities, offering realistic, well-founded proposals rather than maximalist demands. To be taken seriously, one must be credible, transparent, and technically sound.  

What are the industry’s biggest challenges currently, and what is needed to further advance medical cannabis in Germany? 

The biggest challenge remains access to medical treatment with cannabis. Many patients still encounter obstacles when trying to obtain prescriptions and have the costs covered by health insurance companies. Additionally, there is growing uncertainty regarding prescriptions issued via telemedicine, despite their potential to bridge significant care gaps, particularly for chronically ill and mobility-impaired individuals. Therefore, Germany needs a modern, patient-oriented healthcare system; comprehensive education and training in the medical field; and a political framework that promotes investment in quality, research, and security of supply. The BPC is actively contributing to the political debate with concrete proposals. Medical cannabis is no longer a niche topic but an integral part of modern, evidence-based healthcare. 

Thank you very much for the interview!  

Changes are to be expected with the start of this new legislative period. In this context, the work of the BPC is particularly important to advance patients’ interests. Thank you, Antonia Menzel, for the interesting conversation, and best wishes to the association for continued success! 

Upcoming BPC events: 

• Educational webinars: July 9, 2025, on “The Start and Course of Cannabis Therapy” and “Cannabis Medicines: From Theory to Practice” 

Registration: https://bpc-deutschland.de/fortbildungs-webinare/ 

• BPC Symposium 2025 “Cannabinoids in Medicine” for physicians and pharmacists on November 8, 2025, in Düsseldorf – save the date! 

Click here to view the association’s position papers. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

Industry Gathering in Transition: Medicine Meets Business  

In response to last year’s chaotic entry situations and crowded halls, the organizers have announced extensive improvements: more space on the grounds, optimized entrance controls, and extended opening hours are intended not only to enhance visitor comfort but also to specifically promote exchange among professionals. Especially for the medical and business sectors, this means more room for in-depth discussions and networking. At the same time, space for cultural booths and scene stands remains intact—a unique mix that enables dialogue and breaks down barriers. 

Zero Tolerance for Synthetic Cannabinoids  

A clear signal for product safety: Last year, inferior synthetic cannabinoids like HHC repeatedly caused health incidents. The organizers have responded by tightening controls to ensure unauthorized substances do not even enter the halls. We hope these measures will be effective and make Mary Jane 2025 a completely safe event for all attendees—whether from the recreational crowd or professional audiences. 

New B2B Day – Knowledge Meets Business  

On June 19, Mary Jane Berlin hosts the first-ever International B2B Day in cooperation with Business of Cannabis: industry leaders, entrepreneurs, and investors will meet exclusively to forge partnerships and shape the European market. Workshops and roundtables will cover topics from regulatory updates and reimbursement models to telemedicine offerings. Benedikt will also participate in the panel “Building a Resilient Supply Chain: Balancing Domestic Production vs International Imports,” discussing challenges and opportunities of hybrid supply chain models for medical cannabis in Germany. 

Cannabis Industry Conference – Deep Dive on June 20  

On Friday, June 20, 2025, Mary Jane opens its doors at the northern exhibition grounds for the Cannabis Industry Conference. The first part focuses on the review of the past year, followed by discussions on investments, innovations, and political reforms. A comprehensive program offers insights from practical implementation to policy-level debates. 

Closing Thoughts  

Mary Jane 2025 offers a unique experiment in uniting recreational and professional tracks. This format has the potential to foster valuable exchange, innovation, and destigmatization—but the expo must prove it can sustain this balance over the long term. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

Nina Warken – the New Federal Minister of Health 

Since May 2025, Nina Warken (CDU) is leading the Federal Ministry of Health, succeeding Karl Lauterbach. Warken has expressed reservations about general cannabis legalization, calling parts of the existing Cannabis Act a “dubious success.” Warken is relatively unknown outside specialist political circles, yet she now faces the large challenges of hospital reform, strengthening elder and long-term care, and stabilizing health insurance finances. It remains to be seen whether her fresh perspective will drive changes in cannabis regulation—from pharmacy sales to potential coffee shop models. 

Tino Sorge & Dr. Georg Kippels – the New Parliamentary State Secretaries 

Under Minister Warken, Tino Sorge and Dr. Georg Kippels serve as Parliamentary State Secretaries, supporting the health ministry on both organizational and policy matters. Sorge, formerly the health policy spokesperson for the CDU/CSU, and Kippels, with extensive experience in medicine supply and pharmacy policy, represent continuity within the Union: both view the legalization of cannabis for recreational purposes with skepticism, yet medical cannabis holds a firm place in the Union’s treatment of serious illnesses. Their key role is to coordinate technical questions between the parliament and the ministry. 

The New Health Committee – Who’s Making the Decisions? 

The Bundestag’s Health Committee has been constituted with 38 members, chaired by Dr. Tanja Machalet (SPD). With 13 members from the CDU/CSU, seven from the SPD, five from the Greens, and four from The Left, the committee brings together seasoned health policy veterans and fresh voices. This mix promises new energy while maintaining continuity in the parliamentary work on cannabis legislation. Feel free to reach out directly to your health policymakers in your constituency to bring your concerns into the political process! 

Looking Ahead: The CanG Evaluation as a Turning Point 

This autumn will see the launch of the open‑ended evaluation of the Cannabis Act. The EKOCAN research project is already in progress, monitoring the impact of the Cannabis Act on recreational use. Scientists are comprehensively analyzing the law’s effects on child and youth protection, public health, and cannabis‑related crime. The findings will form the basis for any necessary adjustments. At a recent parliamentary evening with the Cannabis Industry Association (BvCW), Carmen Wegge (SPD) confirmed that repealing the Cannabis Act is off the table. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

New Bioactive Compounds from Natural Product Chemistry 

An example of cutting-edge basic research comes from Jung et al. (Pharmaceuticals 2025;18(4):521). The authors were the first to isolate two previously unknown cannabinoids – including cannabielsoxa – as well as chlorin-type metabolites from the flowers of Cannabis sativa. While classic cannabinoids demonstrated strong antitumor effects against neuroblastoma cells in cell culture, the chlorin derivatives open up an entirely new therapeutic avenue: their light-activated properties could be used in photodynamic treatments to selectively destroy tumor cells. For cancer patients whose standard therapies have reached their limits, these newly discovered compounds may become a valuable addition in the future. 

Long-Term Real-World Data from Australia 

The QUEST initiative provides impressive real-world evidence. In a prospective cohort of 2,353 patients treated with medical cannabis oil, quality of life and symptoms such as pain and fatigue improved within a few weeks and remained stable over twelve months. Remarkably, 70% of participants who had previously relied on opioids were able to reduce or completely discontinue their opioid dosage. Such practice-oriented observations are essential for demonstrating that medical cannabis should not be reserved as a last resort but integrated as a core part of modern pain therapy. 

Cannabis for Chemotherapy-Induced Nausea 

Grimison et al. investigated in a large Phase II/III study whether THC:CBD capsules could relieve nausea and vomiting in patients experiencing severe symptoms despite standard antiemetic prophylaxis. Participants took 2.5 mg THC plus 2.5 mg CBD or placebo three times daily. The result: With the cannabis extract, the rate of complete response (no vomiting, no rescue medications) rose from 8% to 24% – a statistically significant increase of 16% (95% CI 4–28; p = 0.01). Episodes of significant nausea, daily vomiting occurrences, and quality-of-life scores also improved. Side effects were mostly mild (sedation, dizziness, transient anxiety), with no serious adverse events. Even moderate doses thus proved to be an effective complement to antiemetic therapy. 

Conclusion & Outlook 

The studies presented here are just a snapshot, but they expand our understanding of new therapeutic opportunities – from innovative antitumor approaches to alleviating treatment-related side effects. They also highlight where research priorities should lie: closing the gap between clinical trials and real-world practice so that medical cannabis gains further precision and trustworthiness, and finds more frequent integration into everyday prescribing. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

Switzerland: From Pilot Projects to a National Cannabis Law 

For over a year now, pilot projects have been running in several Swiss cities to test regulated cannabis distribution. Initial results, recently published by the Federal Office of Public Health (FOPH), provide insights into user behavior and how the projects are being implemented (link to results). Now, Switzerland is taking the next step: In February, the National Council’s Committee for Social Security and Health (SGK-N) presented a draft bill for the comprehensive regulation of cannabis, with a strong focus on public health and youth protection. 

Under the proposal, adults would be allowed to legally consume, grow, and purchase cannabis under clearly defined conditions. Sales would be strictly state-controlled and non-profit, with neutral packaging, health warnings, and a THC-based regulatory tax. The cantons would be responsible for oversight and prevention programs. The next step: a detailed explanatory report will be published in summer, followed by a public consultation with stakeholders and associations. This would pave the way for formal legislative proceedings. 

The Netherlands: A Legal Supply Chain to Replace the Grey Zone 

At the same time, all eyes are on the Netherlands, where the final phase of the “Experiment gesloten coffeeshopketen” (closed coffee shop supply chain experiment) began on April 7, 2025. In participating municipalities, coffee shops are now allowed to sell only regulated, legally produced cannabis. Until now, cannabis sales have been tolerated, but its production remained illegal — a contradiction the experiment aims to resolve. The goal is to establish a fully closed, government-monitored supply chain that ensures product safety and weakens the black market. 

To help ensure a stable supply, especially of hashish, a temporary grace period has been introduced: for the first two months, authorities will not penalize shops that still rely on unregulated hash. By June, only legally regulated products will be allowed. The entire project is accompanied by an independent scientific study evaluating its impact on public health, crime, safety, and public order. 

What Europe Can Learn 

A clear pattern is emerging in both countries: a pragmatic approach to cannabis policy that acknowledges social realities while prioritizing control, prevention, and consumer safety. In the Netherlands, producers are given time to scale up, while Switzerland is building on the experience from its pilot programs to draft a sustainable national policy. 

What lessons can Germany draw from this? First, that regulation is feasible — when planned and implemented thoughtfully. Second, that Europe is slowly but surely moving away from blanket prohibition. Instead, real-world models are being developed to show how responsible cannabis regulation can work. Switzerland and the Netherlands are showing the way. It’s time for Germany to take a closer look — and stop delaying the next phase of its own cannabis policy. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

Review of the Political Debate 

Over the past year, discussions have centered on both the opportunities and challenges of the new law. A key question remains: Have the reforms led to tangible benefits for society and public health? Critics point to gaps in prevention efforts, concerns about youth protection, and potential burdens on the justice system and schools. Supporters argue that no alarming trends have emerged so far and highlight the positive effects of decriminalization, particularly for those previously stigmatized. Beyond public health, the economic impact is also significant. The medical cannabis industry continues to grow, with many mid-sized businesses successfully adapting to the new regulatory landscape. 

Medical Cannabis: Stability or Uncertainty? 

Medical cannabis access has improved with more doctors prescribing it and fewer bureaucratic hurdles for patients. However, challenges remain. Will the CanG stay in place as it is, or will further adjustments be made? The answer is critical for patients, healthcare providers, and businesses alike. 

A full rollback of the law would have major consequences—disrupting treatment for patients, creating uncertainty for doctors and pharmacies, and adding unnecessary bureaucratic complexity. However, targeted adjustments, such as refining enforcement tools to combat the illegal market, could be implemented without undoing the core reforms. 

Scientific Findings and the Road Ahead 

Early research offers some insights: Data from Stuttgart, for example, suggests no significant rise in cannabis use since the law took effect. But a comprehensive evaluation will take time. More data is needed to guide future adjustments based on real-world evidence. 

What’s Next? 

One year later, Germany has not only adapted to cannabis reform—it has proven resilient. Removing cannabis from the Narcotics Act was a crucial step in improving medical access and reducing stigma. The next phase is critical: Thoughtful decisions must be made to ensure progress continues, without political reversals that could undermine the positive developments achieved so far. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

Last week, the German Pain and Palliative Care Days 2025 took place in Frankfurt. Among the numerous lectures and workshops, the use of cannabinoids was a recurring theme throughout the event. Approximately 14 million people in Germany suffer from chronic pain – a serious public health issue that severely affects daily life and is often associated with psychological burdens. It is all the more important that the use of cannabinoids in pain medicine continues to gain significance. 

Cannabinoids in Pain Therapy 

Cannabinoids work through the body’s endocannabinoid system by reducing inflammation, dampening nerve irritations, and influencing pain processing in the brain. In palliative care, they also alleviate nausea and improve sleep. 

Cannabinoids exert their effects through two main receptors. CB1 receptors, primarily found in the central nervous system, inhibit neurotransmitter release and reduce the perception of pain. CB2 receptors, primarily located in immune cells, contribute to anti-inflammatory effects by decreasing the release of pro-inflammatory cytokines. 

Cannabinoids as an Alternative or Complement to Opioids 

Studies have shown that cannabinoids can be used both as a complement to and an alternative to opioids. A 2017 patient survey with 2,897 participants reveals impressive results. 78% of respondents reported better pain reduction compared to pure opioid therapy, 88% found the side effect profile more favorable, and 97% were able to reduce their opioid dosage. These numbers highlight the potential of cannabinoids, particularly in minimizing opioid-associated risks like addiction and side effects. 

Regulatory Challenges and Future Outlook 

The motto of the congress was “Individualization instead of Standardization” – a reflection of how urgently we need to bridge the gap between scientific knowledge and the specific needs in pain therapy. Practical reports show that, despite growing acceptance of cannabinoid-based medications, doctors are often faced with strict regulations and complex procedures before they can issue prescriptions covered by statutory health insurance (GKV). 

Therefore, it is crucial to simplify the prescription processes and integrate cannabinoids more strongly into the established pain therapy guidelines. Only through targeted research and reducing regulatory barriers can we ensure that patients receive the best possible support they need. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

What is the Endocannabinoid System?

The Endocannabinoid System (ECS) is a complex network of natural compounds, receptors, and enzymes present in the human body. It influences various physiological processes, including pain regulation, brain development, appetite, reproduction, and gut motility.[1] This system is found in nearly all living organisms—except insects—highlighting its essential importance for vital body functions. The ECS is named after the discovery that certain compounds from the cannabis plant, known as phytocannabinoids, can have effects similar to those of endogenous cannabinoids produced by the body. The primary psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), binds to the same receptors as these natural substances.

Although the ECS was discovered in the 1960s, many of its functions remain incompletely understood. Its gender-specific effects, in particular, have not been adequately explored.

Why is the ECS Relevant for Women’s Health?

It is well established that the ECS is closely linked to hormonal processes. Studies show that it plays a role in regulating the menstrual cycle, fertility, and menopause.[2][3] The potential for treating female-specific conditions such as endometriosis, premenstrual syndrome (PMS), or chronic pain is particularly intriguing. The ECS could be a key to new therapeutic approaches; however, there are currently few targeted clinical studies examining medical cannabis for these indications.

A better understanding of the ECS is not only scientifically desirable but also urgently needed. Women are often overlooked in medical research, and many of their ailments remain underdiagnosed or inadequately treated. Medical cannabis could offer an alternative or complementary option, especially for patients who do not respond sufficiently to conventional therapies. Furthermore, women tend to experience chronic pain more frequently, which is one of the most common applications of medical cannabis. Therefore, it is even more important to investigate pain perception and the response to pain medication from a gender-specific perspective.[4]

Why We Need More Gender-Specific Research

On the occasion of this year’s International Women’s Day, it is time to bring this topic into sharper focus. A better understanding of the ECS could not only help to apply medical cannabis more effectively but also open new doors for personalized medicine. A gender-specific approach in cannabis research is long overdue.

[1] Fowler, C. J. (2010). Anandamide uptake explained? Trends in Pharmacological Sciences, 33(4), 181–185.
[2] Santoro, A., Mele, E., Marino, M., Viggiano, A., Nori, S. L., & Meccariello, R. (2021). The complex interplay between the endocannabinoid system and the estrogen system in the central nervous system and periphery. International Journal of Molecular Sciences, 22(2), 972. https://doi.org/10.3390/ijms22020972
[3] Di Blasio, A. M., Vignali, M., & Gentilini, D. (2013). The endocannabinoid pathway and the female reproductive organs. Journal of Molecular Endocrinology, 50(1), R1-9. https://doi.org/10.1530/JME-12-0182
[4] Schmerzgesellschaft. (n.d.). Schmerz bei Frauen und Männern. Abgerufen von https://www.schmerzgesellschaft.de/patienteninformationen/besonderheiten-bei-schmerz/schmerz-bei-frauen-und-maenner

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,

International Industry Meetings: Exchange at the Highest Level

Germany remains a key player in the European cannabis industry. The ICBC Berlin (April 29-30, 2025) is the leading international event for the German market, bringing together businesses, investors, and policymakers. Market developments are discussed here, partnerships are forged, and the next steps for the industry are shaped.

Focusing on the medical sector, the Medical Cannabis Congress (June 12-13, 2025) in Berlin provides a dedicated platform for physicians, scientists, and pharmacists to discuss the latest advancements in cannabis therapy.
Similarly, the German Pain and Palliative Care Congress (March 12-16, 2025) in Frankfurt will explore the role of medical cannabis—especially in pain management, which has gained new momentum following regulatory changes last year.
The discussion on Europe’s cannabis market extends beyond national borders. In London, Cannabis Europa (June 24-25, 2025) will focus on regulatory developments, economic opportunities, and industry challenges across the continent. This event is particularly relevant for companies and investors looking to expand internationally.

Germany as a Hub for Cannabis Events

Germany continues to establish itself as a central hub for cannabis events. Mary Jane Berlin (June 19-22, 2025) remains one of Germany’s largest hemp fairs and is unique in covering all aspects of the industry: adult-use cannabis, CBD, industrial hemp, and medical cannabis. The event attracts tens of thousands of visitors annually—including consumers, activists, and businesses—making it a key meeting point for the entire industry.

For professionals in the pharmaceutical industry and the pharmacy sector, Expopharm in Düsseldorf (September 18-20, 2025) is an essential event. With a growing focus on medical cannabis, the role of pharmacies in patient care is becoming increasingly significant. This trade show serves as a key platform for stakeholders involved in the distribution, prescription, and application of medical cannabis.

Looking Beyond Borders: Global Highlights

For those looking to connect with the international cannabis industry, MJBizCon in Las Vegas (December 2-5, 2025) is an unmissable event. As the world’s largest cannabis trade show, it attracts tens of thousands of attendees from all sectors of the industry—from producers and brand developers to investors and policymakers.

The Future of Cannabis: What Lies Ahead in 2025

The cannabis industry remains in motion, and 2025 promises to be a year of exciting developments. The range of upcoming events highlights the industry’s dynamism and innovative potential—both in Germany and globally.

Whether it’s regulatory milestones, medical breakthroughs, or new business models, the coming months will be pivotal. We look forward to following these developments with you and engaging in discussions at one of these key events.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,